Characterization of C3 in C3 glomerulopathy

被引:41
|
作者
Sethi, Sanjeev [1 ]
Vrana, Julie A. [1 ]
Fervenza, Fernando C. [2 ]
Theis, Jason D. [1 ]
Sethi, Amit [3 ]
Kurtin, Paul J. [1 ]
Zhang, Yuzhou [4 ,5 ]
Smith, Richard J. H. [4 ,5 ]
机构
[1] Mayo Clin, Dept Lab Med & Pathol, 200 1st St SW, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Internal Med, Div Nephrol & Hypertens, Rochester, MN USA
[3] Mayo High Sch, Rochester, MN USA
[4] Carver Coll Med, Dept Internal Med, Div Nephrol, Mol Otolaryngol & Renal Res Labs, Iowa City, IA 52242 USA
[5] Carver Coll Med, Dept Pediat, Div Nephrol, Mol Otolaryngol & Renal Res Labs, Iowa City, IA 52242 USA
关键词
C3; glomerulonephritis; glomerulopathy; C3dg; complement; dense deposit disease; HEMOLYTIC-UREMIC SYNDROME; DENSE DEPOSIT DISEASE; MASS-SPECTRAL DATA; ALTERNATIVE PATHWAY; SEQUENCE DATABASES; COMPLEMENT; GLOMERULONEPHRITIS; DYSFUNCTION; PROTEOMICS;
D O I
10.1093/ndt/gfw290
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background: C3 glomerulopathy (C3G) is caused by overactivity of the alternative pathway of complement that results in bright glomerular C3 staining with minimal or no deposition of immunoglobulins on immunofluorescence microscopy. Laser microdissection and mass spectrometry of the two subtypes, C3 glomerulonephritis (C3GN) and dense deposit disease (DDD), have identified C3 as the predominant glomerular complement protein, although lesser amounts of C9, C5, C6, C7 and C8 are detectable. C3 plays a central role in complement activity, with its proteolytic cleavage first generating C3a and C3b, followed by inactivation of C3b generating iC3b (which includes C3a and C3b), which undergoes further breakdown yielding C3c and terminal breakdown fragment C3dg. The composition of C3 breakdown products in C3G is not known. Methods: In this study, we chose six cases each of C3GN and DDD to analyze the composition of C3 deposits. We analyzed the amino acid sequence of C3 spectra detected by mass spectrometry to determine the relative abundance of C3 fragments in C3G. Thus we were able to determine the amino acid sequences mapping to the various C3 activation products including C3dg, C3a (C3a1 and a2), and C3b that are part of C3b/iC3b/C3c. Results: C3dg is the predominant cleavage product detected with the highest amino acid coverage. The remaining amino acids map to C3a (C3a1 and a2) and C3b. Amino acids mapping to C3a and C3f are absent. Taken together, the C3a and C3b amino acids represent iC3b prior to or after C3c cleavage of C3dg. The C3 spectra for both C3GN and DDD are surprisingly similar. Conclusion: The finding of large amounts of C3dg suggests that C3b deposition in the glomerulus is an active process triggered by thioester binding of C3b to the glycocalyx overlying the glomerular endothelial cells and glomerular basement membrane. Regulatory protein-mediated inactivation of C3b results in the generation of iC3b. After additional cleavages, mostly C3dg remains.
引用
收藏
页码:459 / 465
页数:7
相关论文
共 50 条
  • [21] Pregnancy Outcomes in C3 Glomerulopathy
    Fergus, Lauren O.
    Hall, Monica D.
    Zhang, Yuzhou
    Smith, Richard J.
    Nester, Carla M.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 684 - 685
  • [22] C3 glomerulopathy: a new classification
    Fakhouri, Fadi
    Fremeaux-Bacchi, Veronique
    Noel, Laure-Helene
    Cook, H. Terence
    Pickering, Matthew C.
    NATURE REVIEWS NEPHROLOGY, 2010, 6 (08) : 494 - 499
  • [23] C3 Glomerulopathy in Children and Adolescents
    Borovitz, Yael
    Alfandary, Hadas
    Dagan, Amit
    Haskin, Orly
    Landau, Daniel
    Davidovits, Miriam
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 487 - 487
  • [24] Treatment options for C3 glomerulopathy
    Nester, Carla M.
    Smith, Richard J.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2013, 22 (02): : 231 - 237
  • [25] C3 glomerulopathy: a new classification
    Fadi Fakhouri
    Véronique Frémeaux-Bacchi
    Laure-Hélène Noël
    H. Terence Cook
    Matthew C. Pickering
    Nature Reviews Nephrology, 2010, 6 : 494 - 499
  • [26] C3 Glomerulopathy in Older Adults
    Lloyd, Isaac
    Huston, Hunter
    Jenkins, Stephen
    Raphael, Kalani
    Miller, Dylan
    Revelo, Monica P.
    Khalighi, Mazdak
    LABORATORY INVESTIGATION, 2016, 96 : 407A - 407A
  • [27] Treating C3 glomerulopathy with eculizumab
    Thomas Welte
    Frederic Arnold
    Julia Kappes
    Maximilian Seidl
    Karsten Häffner
    Carsten Bergmann
    Gerd Walz
    Elke Neumann-Haefelin
    BMC Nephrology, 19
  • [28] POST INFECTIOUS C3 GLOMERULOPATHY
    Shawar, Saed
    Shobana, Sivan
    Hamad, David Sheikh
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2016, 67 (05) : A99 - A99
  • [29] Diagnostic Problems in C3 Glomerulopathy
    Niepolski, Leszek
    Czekala, Anna
    Seget-Dubaniewicz, Monika
    Frydrychowicz, Magdalena
    Talarska-Markiewicz, Patrycja
    Kowalska, Angelika
    Szmelter, Jagoda
    Salwa-Zurawska, Wieslawa
    Sirek, Tomasz
    Sobanski, Dawid
    Grabarek, Beniamin Oskar
    Zurawski, Jakub
    BIOMEDICINES, 2023, 11 (04)
  • [30] Treating C3 glomerulopathy with eculizumab
    Welte, Thomas
    Arnold, Frederic
    Kappes, Julia
    Seidl, Maximilian
    Haeffner, Karsten
    Bergmann, Carsten
    Walz, Gerd
    Neumann-Haefelin, Elke
    BMC NEPHROLOGY, 2018, 19